Russell Investments Group Ltd. Raises Position in Pfizer Inc. $PFE

Russell Investments Group Ltd. grew its holdings in Pfizer Inc. (NYSE:PFE) by 15.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,482,863 shares of the biopharmaceutical company’s stock after acquiring an additional 745,213 shares during the period. Russell Investments Group Ltd.’s holdings in Pfizer were worth $132,365,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also modified their holdings of the company. Vermillion Wealth Management Inc. boosted its holdings in Pfizer by 19.4% in the first quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock valued at $66,000 after purchasing an additional 382 shares during the period. Eagle Capital Management LLC increased its holdings in Pfizer by 0.3% during the 1st quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock worth $3,554,000 after purchasing an additional 390 shares during the period. Delta Financial Advisors LLC raised its position in Pfizer by 1.6% in the 1st quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock valued at $709,000 after purchasing an additional 398 shares in the last quarter. Pines Wealth Management LLC boosted its stake in shares of Pfizer by 4.4% in the 4th quarter. Pines Wealth Management LLC now owns 9,430 shares of the biopharmaceutical company’s stock valued at $235,000 after buying an additional 400 shares during the period. Finally, Mount Vernon Associates Inc. MD grew its position in shares of Pfizer by 1.0% during the first quarter. Mount Vernon Associates Inc. MD now owns 41,919 shares of the biopharmaceutical company’s stock worth $1,177,000 after buying an additional 400 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE PFE opened at $27.83 on Friday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. Pfizer Inc. has a 1 year low of $23.58 and a 1 year high of $28.75. The company has a market capitalization of $158.62 billion, a PE ratio of 36.62 and a beta of 0.34. The company has a fifty day moving average of $25.27 and a two-hundred day moving average of $26.24.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. The business had revenue of $15.03 billion for the quarter, compared to analysts’ expectations of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The business’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts expect that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be given a $0.43 dividend. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 6.2%. Pfizer’s dividend payout ratio is 226.32%.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer shares benefited from renewed enthusiasm for cancer vaccines after Merck and Moderna reported positive melanoma-trial results for their personalized mRNA vaccine and Keytruda combination. The news has encouraged investors to reassess Pfizer’s own cancer-vaccine ambitions and broader mRNA exposure. Pfizer Stock Rises Wednesday: What’s Going On?
• Positive Sentiment: Pfizer’s obesity strategy remains a potential long-term catalyst. Investors are watching berobenatide, a possible monthly treatment intended to compete with leading GLP-1 drugs and help diversify revenue beyond legacy products. Pfizer’s Obesity Push
• Positive Sentiment: Pfizer’s high dividend yield and recent share performance are attracting income-oriented investors. Recent filings also indicate substantial hedge-fund buying, while unusually heavy call-option activity points to improving speculative sentiment. Yield Hunters and Hedge-Fund Buying
• Neutral Sentiment: Pfizer completed a real-world study evaluating Ibrance in advanced breast cancer. The study’s completion could provide useful evidence for the product, but investors are awaiting the data and any commercial implications. Pfizer’s Ibrance Study Update
• Negative Sentiment: Pfizer is settling thousands of Depo-Provera lawsuits alleging a link to intracranial meningiomas. While a settlement program may reduce litigation uncertainty, it also highlights potentially significant financial exposure and keeps legal risk overhanging the stock. Why Is Pfizer Settling Thousands of Legal Claims?
• Negative Sentiment: Investors remain focused on Pfizer’s patent cliff. New and acquired medicines may replace much of the revenue lost as older patents expire, but the transition leaves limited room for execution errors and raises concerns about longer-term growth. Pfizer Stock Is a Race Between New Drugs and Old Patents
• Negative Sentiment: Merck’s deeper investment in personalized cancer vaccines raises the competitive bar for Pfizer and could make it harder for Pfizer to establish a leading position in this emerging market. Merck Raises the Stakes for Pfizer’s Cancer Vaccine Ambitions

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. UBS Group restated a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research note on Wednesday, May 27th. JPMorgan Chase & Co. lowered their price target on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a report on Wednesday, July 8th. Cantor Fitzgerald restated a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a report on Monday, July 6th. HSBC downgraded shares of Pfizer from a “buy” rating to a “hold” rating and lowered their target price for the stock from $32.00 to $28.00 in a research note on Monday, July 6th. Finally, Weiss Ratings cut Pfizer from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $28.28.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.